Early versus late hormonal therapy: Debating the issues

Urology

Volumn 61, Issue 2 SUPPL., 2003, Pages 8-13

  Crawford, E David ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTIINFECTIVE AGENT; GONADORELIN AGONIST; MITOXANTRONE;

ADJUVANT CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL TRIAL; HORMONAL THERAPY; HUMAN; IRRADIATION; MALE; METASTASIS; NOMOGRAM; PALLIATIVE THERAPY; PELVIS LYMPHADENECTOMY; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RELAPSE; REVIEW;

EID: 0037298842     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)02394-4     Document Type: Article

References (32)

1. Forster T.H., Stoffel F., Gasser T.C. Hormone therapy in advanced prostate cancer. Front Radiat Ther Oncol. 36:2002;49-65.
2. Vis A.N. Does PSA screening reduce prostate cancer mortality? [commentary] CMAJ. 166:2002;600-601.
3. Perron L., Moore L., Bairati I., et al. PSA screening and prostate cancer mortality. CMAJ. 166:2002;586-591.
4. Prostate-specific antigen (PSA) best practice policy. Oncology (Huntingt). 14:2000;267-280.
5. Roach M., Lu J., Pilepich M.V., et al. Predicting long-term survival, and the need for hormonal therapy a meta-analysis of RTOG prostate cancer trials . Int J Radiat Oncol Biol Phys. 47:2000;617-627.
6. Crawford E.D., Blumenstein B.A. Proposed substages for metastatic prostate cancer. Urology. 50:1997;1027-1028.
7. National Comprehensive Cancer Network: Prostate cancer. Treatment guidelines for patients. Version II. Last update: 2001. Available at: http://www.nccn.org/patient_gls/_english/_prostate_cancer/index.htm . Accessed July 2, 2002.
8. D'Amico A. Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer. Urology. 58:(suppl 2A):2001;78-82.
9. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281:1999;1591-1597.
10. Crawford E.D., Rosenblum M., Ziada A.M., et al. Overview hormone refractory prostate cancer . Urology. 54:(6A suppl):1999;1-7.
11. Crawford D., Faulkner J., Thompson I.M., et al. Ten-year survival in patients with metastatic (M+) prostate cancer (CAP) analysis of Southwest Oncology Group (SWOG) 8894 . [abstract] J Urol. 167:2002;304.
12. Harris K.A., Reese D.M. Treatment options in hormone-refractory prostate cancer current and future approaches . Drugs. 61:2001;2177-2192.
13. Byar DP, and Corle DK: Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 165-170, 1988.
14. Immediate versus deferred treatment for advanced prostatic cancer initial results of the Medical Research Council Trial . Br J Urol. 79:1997;235-246.
15. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 337:1997;295-300.
16. Pilepich M.V., Krall J.M., Al-Sarraf M., et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma a randomized comparative trial of the Radiation Therapy Oncology Group . Urology. 45:1995;616-623.
17. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 341:1999;1781-1788.
18. Pilepich M.V., Winter K., John M.J., et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 50:2001;1243-1252.
19. Horwitz E.M., Winter K., Hanks G.E., et al. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long- term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys. 49:2001;947-956.
20. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol. 166:2001;2185-2188.
21. Cadeddu J.A., Partin A.W., Epstein J.I., et al. Stage D1 (T1-3, N1-3, M0) prostate cancer a case-controlled comparison of conservative treatment versus radical prostatectomy . Urology. 50:1997;251-255.
22. Seay T.M., Blute M.L., Zincke H. Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol. 159:1998;357-364.
23. Graefen M., Karakiewicz P.I., Cagiannos I., et al. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol. 20:2002;951-956.
24. Ross P.L., Gerigk C., Gonen M., et al. Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol. 20:2002;82-88.
25. Duric V., Stockler M. Patients' preferences for adjuvant chemotherapy in early breast cancer a review of what makes it worthwhile . Lancet Oncol. 2:2001;691-697.
26. Macdonald J.S., Astrow A.B. Adjuvant therapy of colon cancer. Semin Oncol. 28:2001;30-40.
27. Mamounas E.P. Present state and future prospects a review of cooperative groups' adjuvant and neoadjuvant trials in breast cancer . Clin Breast Cancer. 2:(suppl 1):2001;S20-S30.
28. Midgley R., Kerr D. Conventional cytotoxic and novel therapeutic concepts in colorectal cancer. Expert Opin Investig Drugs. 10:2001;1011-1019.
29. Chay C., Smith D.C. Adjuvant and neoadjuvant therapy in prostate cancer. Semin Oncol. 28:2001;3-12.
30. Wang J., Halford S., Rigg A., et al. Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int. 86:2000;675-680.
31. DiPaola R.S., Chenven E.S., Shih W.J., et al. Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma. Cancer. 92:2001;2065-2071.
32. Crawford E.D. Immediate versus delayed therapy for prostate cancer. Fam Urol. 6:2002;18-21.